ODI — Odi Pharma AB (publ) Income Statement
0.000.00%
Last trade - 00:00- SEK41.06m
- SEK35.70m
- SEK22.29m
Annual income statement for Odi Pharma AB (publ), fiscal year end - June 30th, SEK millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | SAS | SAS | SAS | SAS | SAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0.313 | 0.139 | 22.3 |
| Cost of Revenue | |||||
| Gross Profit | — | — | -5.6 | -5.69 | -0.295 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 4.93 | 3.96 | 7.52 | 6.95 | 21.9 |
| Operating Profit | -4.93 | -3.96 | -7.21 | -6.81 | 0.428 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -4.94 | -3.97 | -7.24 | -6.9 | -0.379 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -4.96 | -3.98 | -7.24 | -6.9 | -0.568 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -4.96 | -3.98 | -7.24 | -6.9 | -0.568 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -4.96 | -3.98 | -7.24 | -6.9 | -0.568 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.359 | -0.26 | -0.475 | -0.453 | -0.037 |
| Dividends per Share |